Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lapatinib + trastuzumab + single-agent chemotherapy for HER2-positive metastatic breast cancer
ChiCTR1800015814Phase 2Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and trastuzumab in breast cancer, sponsored by Foshan First People's Hospital. Primary endpoint: Progression-free survival. Planned start May 2018; status: not yet recruiting.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800015814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015814.